Host Langerhans cells (LCs) can be therapeutically manipulated In vivo with imiquimod (TLR7 agonist) to augment DLI-mediated GVH and GVL reactivity
Skarica M, Radojcic V, Luznik L. Host Langerhans cells (LCs) can be therapeutically manipulated In vivo with imiquimod (TLR7 agonist) to augment DLI-mediated GVH and GVL reactivity. Transplantation And Cellular Therapy 2006, 12: 52. DOI: 10.1016/j.bbmt.2005.11.164.Peer-Reviewed Original Research